Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

To learn if sacituzumab govitecan can help to control salivary gland cancer.

Trial Details

NCT ID
NCT05884320
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Salivary Gland Head and Neck Cancer
Interventions
  • Sacituzumab Govitecan
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • All patients must meet all of the following inclusion criteria to be eligible for participation in this study:
  • Patients ≥18 years with histology-proven R/M salivary gland cancer.
  • Not amenable to curative intent surgery or radiotherapy
  • Measurable disease per RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Salivary Gland Head and Neck Cancer Trials on Trialify →